Britain and America have agreed to a key commercial pact that will keep zero tariffs on British medicine exports being sold in the US market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has agreed to raise spending on drugs through the NHS. This pledge ensures that import taxes on these crucial exports will stay at nothing for a period of 36 months.
This development is in response to earlier statements to dramatically increase tariffs on branded drug products, with potential rates floated reaching double the cost.
"This arrangement between the UK strengthens the worldwide climate for new treatments and introduces much-needed equity to American-British drug exports," an announcement said.
Commercial Importance
Drugs are one of the Britain's largest exports to the United States, which is clearly the primary buyer for leading companies like GSK and AstraZeneca.
Trade data indicate that in the one-year period prior to the third quarter, the UK shipped pharmaceutical products totaling £11.1bn to the US. This figure accounted for nearly one-fifth of all goods exports in that span.
"This agreement safeguards work, stimulates investment and facilitates the UK to emerge as a international leader for life sciences," the Business and Trade Secretary stated.
Key UK Commitments
The agreement entails several specific commitments from the UK:
- Revised Affordability Limit: The UK will lift the cost ceiling at which it considers new treatments to be unaffordable by 25%.
- Higher Drug Budget: There is a goal to double overall health service expenditure on medicines from 0.3% of GDP to 0.6 percent over the next decade.
- Refund Ceiling: The sum drug companies must pay back to the NHS to prevent overspending will be limited at 15%. Last year, rebates exceeded twenty percent.
Broader Context
This agreement follows a long-running dispute between the sector and the ministers over spending levels and approval rates.
These tensions were intensified by arguments that American consumers were charged several times more for the same drugs than patients in the other developed nations.
Over the last 18 months, several major drug company projects in the UK have been paused or cancelled, while substantial investments have been directed toward US facilities.
One official stated that the NHS had to spend more on drugs, noting that its spending on drugs had declined as a percentage of its overall budget over the previous ten-year period.
